0000899243-19-002330.txt : 20190201
0000899243-19-002330.hdr.sgml : 20190201
20190201164243
ACCESSION NUMBER: 0000899243-19-002330
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190131
FILED AS OF DATE: 20190201
DATE AS OF CHANGE: 20190201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Edick Paul R
CENTRAL INDEX KEY: 0001531178
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38536
FILM NUMBER: 19560345
MAIL ADDRESS:
STREET 1: C/O NEWLINK GENETICS CORP.
STREET 2: 2503 SOUTH LOOP DR., SUITE 5100
CITY: AMES
STATE: IA
ZIP: 50010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: XERIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001346302
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203352427
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 180 NORTH LASALLE STREET
STREET 2: STE 1800
CITY: CHICAGO
STATE: IL
ZIP: 60601
BUSINESS PHONE: 512-498-2670
MAIL ADDRESS:
STREET 1: 180 NORTH LASALLE STREET
STREET 2: STE 1800
CITY: CHICAGO
STATE: IL
ZIP: 60601
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-01-31
0
0001346302
XERIS PHARMACEUTICALS INC
XERS
0001531178
Edick Paul R
C/O XERIS PHARMACEUTICALS, INC.
180 N. LASALLE STREET, SUITE 1810
CHICAGO
IL
60601
1
1
0
0
See Remarks
Common Stock
2019-01-31
4
A
0
125000
0.00
A
125000
D
Common Stock
13430
I
By: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018
Stock Option (right to buy)
13.88
2019-01-31
4
A
0
200000
0.00
A
2029-01-31
Common Stock
200000
200000
D
These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. 25% of these restricted stock units shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months.
The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months.
Chairman, President & Chief Executive Officer
/s/ Beth Hecht, as Attorney-in-Fact
2019-02-01